English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

activity is not clarified. The goal of this research is to examine the ability of 3-(3-[1,2,4]triazolo)-oxatriazolium-5-olate (AS-6) to generate NO, to activate sGC, and to alter systemic arterial pressure at awake rats. The ability of AS-6 to generate NO was estimated by its reaction with oxyhemoglobin in the presence and absence of glutathione. Also NO (nitrite) formation in the presence of AS-6 was measured by the Griess reaction. Activity of sGC was measured by using purified enzyme from porcine lung in the presence of 10-200 microM AS-6 with alpha[P]GTP as a substrate. To examine hypotensive activity of AS-6 male Wistar rats (200-300 g weight) were catheterized and mean arterial pressure was measured. AS-6 was administrated at doses 0.012-120 mg/kg to rats of experimental group in two days. Control group were administrated with corresponding DMSO solutions. We demonstrated that AS-6 doesn’t generate detectable levels of NO both in the presence and absence of glutathione. AS-6 activated purified sGC in dose-dependent manner with 22-fold maximal activation. This activation could be potentiated by allosteric sGC activator YC-1 and completely blocked by heme-dependent sGC inhibitor ODQ. In vivo AS-6 caused MAP decrease, 5.4 and 8.4 mm Hg, (p 0.05) at doses 12 and 120 mg/kg, respectively. MAP was significantly decreased from 15 min and was stably reduced for 15 min. Intravenous administration of AS-6 leads to prolonged arterial pressure decrease in awake rats. It seems to be that AS-6 activates sGC in heme-dependent NO-independent manner.

american journal of hypertension

Avoiding adverse cardiovascular outcomes with prompt blood pressure control: An economic analysis based on the valsartan antihypertensive long-term use evaluation (VALUE) trial